• LAST PRICE
    2.9400
  • TODAY'S CHANGE (%)
    Trending Up0.0600 (2.0833%)
  • Bid / Lots
    2.9200/ 3
  • Ask / Lots
    2.9400/ 2
  • Open / Previous Close
    2.8500 / 2.8800
  • Day Range
    Low 2.8500
    High 3.0300
  • 52 Week Range
    Low 2.6450
    High 8.0250
  • Volume
    55,202
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 2.88
TimeVolumeCRMD
09:32 ET75832.895
09:36 ET2002.9299
09:38 ET32002.97
09:39 ET20002.9951
09:43 ET1003
09:48 ET11302.97
09:50 ET1002.99
09:57 ET3003
10:01 ET17003
10:03 ET1003.02
10:08 ET1002.97
10:12 ET36002.9999
10:14 ET2002.97
10:19 ET1303
10:21 ET93102.98
10:33 ET40482.93
10:37 ET11002.9599
10:39 ET14242.96
10:42 ET1002.94
10:46 ET1002.9509
10:48 ET10002.93
10:50 ET3002.92
10:51 ET21002.92
10:53 ET11002.9156
11:00 ET11292.93
11:11 ET2002.94
11:18 ET21002.92
11:20 ET1002.95
11:24 ET1002.95
11:33 ET13672.95
11:38 ET7002.95
11:45 ET2002.935
11:49 ET8002.95
11:56 ET34132.94
Data delayed at least 15 minutes.
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesCRMD
CorMedix Inc
118.7M
-3.7x
---
United StatesCPLFY
Cipla Ltd
10.6B
0.0x
---
United StatesASMB
Assembly Biosciences Inc
82.3M
-0.6x
---
United StatesALID
Allied Corp
52.3M
-2.4x
---
United StatesNHWK
NightHawk Biosciences Inc
45.9M
-1.1x
---
United StatesNOVN
Novan Inc
37.5M
-0.9x
---
As of 2022-09-26

Company Information

CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's primary focus is on the development of its lead product candidate, DefenCath, for commercialization in the United States. The DefenCath/Neutrolin is an anti-infective solution, a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL intended for the reduction of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings such as hemodialysis and total parenteral nutrition. DefenCath product is available in Europe and other territories under the brand name Neutrolin.

Contact Information

Headquarters
300 Connell Drive, Suite 4200BERKELEY HEIGHTS, NJ, United States 07922
Phone
908-517-9500
Fax
302-636-5454

Executives

Independent Chairman of the Board
Myron Kaplan
Chief Executive Officer, Director
Joseph Todisco
Chief Financial Officer, Executive Vice President
Matthew David
Executive Vice President and General Counsel and Head of Regulatory, Compliance, Legal and Technical Operations
Phoebe Mounts
Executive Vice President - Head of Clinical Operations
Elizabeth Masson-Hurlburt

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$118.7M
Revenue (TTM)
$123.4K
Shares Outstanding
41.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
2.35
EPS
$-0.80
Book Value
$1.65
P/E Ratio
-3.7x
Price/Sales (TTM)
961.9
Price/Cash Flow (TTM)
---
Operating Margin
-25,626.24%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.